Monopar Therapeutics announced that it received notice from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
- Monopar Therapeutics receives HREC clearance in Australian for MNP-101L-u study
- Monopar Therapeutics target adjusted to $9 from $2 at JonesResearch
- Monopar Therapeutics Begins Phase 1 Trial of MNPR-101-Zr
- Monopar announces initial data for first patient dosed in trial of MNPR-101-Zr